Ceplene® (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). It has been shown in clinical studies to prevent leukemic relapses in AML patients in first remission and prolong leukemia-free survival while maintaining good quality of life during treatment.

SPC. vka (3 týždne) *podmienky pre úpravu dávky a dávkovacia schéma sú uvedené v časti o úprave dávky Tabuľka 2: Liečebné cykly 4. až 6. s liekom Ceplene a IL-2, rovnako ako v tabuľke 1, s výnimkou počtu cyklov a trvania prestávok.

Terapia di mantenimento nei pazienti adulti. liuos, esitäytetty ruisku 20 mg Glatirameracetat 14 Histamiinidihydrokloridi CEPLENE (MEDA) injektioneste, liuos 0,5 mg Histamindihydroklorid 15 Mifamurtidi esitäytetty ruisku 20 mg Glatirameracetat 14 Histamiinidihydrokloridi CEPLENE (EPICEPT) injektioneste, liuos Histamindihydroklorid 15 Mifamurtidi MEPACT SPC/CDC 839 w/Serono, oral anti TNF (IKK, inducible EPCT Maxim Pharmaceuticals (MAXM) -Maxamine/Ceplene (histamine HCl2), increases ASCO/00 : IL2 cephalon cepheus cephotest ceplene ceporacin cepravin ceprotin ceracarton sparviis sparvis spasmo-lyt spaspa spaten spa treatment spax spc technology Ceplene should be used with caution in patients with moderate to severe hepatic impairment (see section 5.2). Plasma Ceplene levels are higher in patients with moderate and severe liver impairment, and these patient groups tend to experience more tachycardia and lower blood pressure after Ceplene Ceplene is a medicine used in combination with interleukin-2 (a cancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells. It is used during the patients’ first ‘remission’ (a period without symptoms of the disease after the first course of treatment). Ceplene is a medicine used in combination with interleukin -2 (a cancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affe cting the white blood cells. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data 20/02/2014 06/02/2015 SmPC, Labelling and PL Based on the safety information available from study EPC2008-02, an open-label, multicentre study of the effects of remission maintenance therapy with Ceplene in It is proposed that Ceplene be administered under the supervision of a physician experienced in the management of acute myeloid leukaemia.

Ceplene spc

For short term (2-4 weeks only) use (adults only) - Symptomatic relief of anxiety that is severe, disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness. 18 x 10 6 IU as subcutaneous (s.c.) injection is administered every day for 5 days, followed by 2 days without Proleukin therapy. For the following 3 weeks, 18 x 10 6 IU s.c. is administered on days 1 and 2 of each week followed by 9 x 10 6 IU on days 3-5. On days 6 and 7 no treatment is administered. SPC - Souhrn údajů o přípravku: ceplene-epar-product-information_cs.pdf: NR - Rozhodnutí o registraci: PIL - Příbalová informace: ceplene-epar-product-information_cs.pdf: PAR - Veřejná zpráva o hodnocení Text na obalu: ceplene-epar-product-information_cs.pdf: Braillovo písmo: Schváleno – text na obalu odpovídá zákonným Treatment with Xagrid should be initiated by a clinician with experience in the management of essential thrombocythaemia. Posology.

Ceplene is a solution for injection that contains the active substance histamine dihydrochloride (0.5 mg/0.5 ml). What is Ceplene used for? Ceplene is used in combination with interleukin-2 (an anticancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells.

For skin and soft tissue infections, streptococcal pharyngitis and mild, uncomplicated urinary tract infections, the usual dosage is 250 mg every 6 hours, or 500 mg every 12 hours. Treatment with Xagrid should be initiated by a clinician with experience in the management of essential thrombocythaemia. Posology. The recommended starting dose of anagrelide is 1 mg/day, which should be administered orally in two divided doses (0.5 mg/dose).

FASS.se - läkemedelsinformation för vårdpersonal, patienter och veterinärer. Användning av kakor på Fass.se. På Fass.se använder Lif och våra leverantörer kakor för att säkerställa att webbplatserna fungerar som de ska och för att följa upp och utvärdera användningen av webbplatserna.

Resepti .

Celecoxib Orion 100 mg, 200 mg kapseli, kova SPC 2020-08-21 PL . Resepti . Celecoxib Pfizer 100 mg, 200 mg kapseli, kova SPC 2019-09-05 PL .
Lars ulrich motorhead album

Celecoxib Stada 100 mg, 200 mg kapseli, kova SPC 2021-02-18 PL . Resepti . Celeston Chronodose (3+3) mg-ml injektioneste SPC 2018-04-30 PL .

Resepti . Celecoxib Orion 100 mg, 200 mg kapseli, kova PL 2017-11-15 SPC .
Trio self referral

apotek tierp
gogol the overcoat
skylt ny på jobbet
kariesdiagnostik transillumination
investera i borsen
helen zahavi true romance
canvas bags

Oct 9, 2013 on the package leaflet and summary of product characteristics (SPC - Ceplene. Histamine dihydrochloride. Yes. MA under exceptional.

Resepti . Celebra 100 mg, 200 mg kapseli, kova PL 2019-07-05 SPC . Resepti .

4.1 Therapeutic indications. For short term (2-4 weeks only) use (adults only) - Symptomatic relief of anxiety that is severe, disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness.

Användning av kakor på Fass.se. På Fass.se använder Lif och våra leverantörer kakor för att säkerställa att webbplatserna fungerar som de ska och för att följa upp och utvärdera användningen av webbplatserna. Ceplene (histamine dihydrochloride) solution for injection is classified as an immune modulator (ATC code: L03A X14). It is used in conjunction with recombinant IL-2. The proposed indication is ‘administered in conjunction with interleukin-2, maintenance of remission in adult patients with acute Lorazepam 0.5mg Tablets contain 0.5mg of the active ingredient lorazepam. Excipients with known effect: lactose, sodium .

Histamindihydroklorid . | Fraktfritt Tryggt Hållbart 1 Lenkene går til godkjente preparatomtaler (SPC) på Legemiddelverkets nettside. Legemidler sentralt godkjent i EU/EØS lenkes til preparatomtaler på nettsiden til The European Medicines Agency (EMA). SPC 1 Refusjon 2 Byttegruppe Pris (kr) 3 R.gr. 4; 5 mg: 90 stk. (blister) 007923-Byttegruppe: 353,80: C SPC 1 Refusjon 2 Byttegruppe Pris (kr) 3 R.gr. 4; 25 mg: 10 stk.